...
首页> 外文期刊>Advances in Interventional Cardiology: Postepy w Kardiologii Interwencyjnej >Comparison of the results of transcatheter aortic valve implantation in patients with bicuspid and tricuspid aortic valve
【24h】

Comparison of the results of transcatheter aortic valve implantation in patients with bicuspid and tricuspid aortic valve

机译:双裂和三尖瓣主动脉瓣膜经截管主动脉瓣植入术的比较

获取原文

摘要

Introduction Indications for transcatheter aortic valve implantation (TAVI) are constantly expanding, including younger patients. Bicuspid aortic valves (BAV) often occur in this group. In order to achieve optimal treatment results in younger patients, it is necessary to develop an effective method for selecting the size of implanted valves. Aim: To compare the results of TAVI with use of a?self-expanding prosthesis in patients with a?BAV and a?tricuspid aortic valve (TAV) with valve selection based on annular sizing. Material and methods The diagnosis of BAV and TAV and measurements (annular sizing) were based on multi-slice computed tomography scans. Eighty-three patients received a?self-expanding CoreValve or Evolut R prosthesis. In group I?(BAV) there were 21 (25.3%) patients and in group II (TAV) there were 62 (74.7%) patients. Results The groups did not differ in terms of baseline clinical characteristics. Device success was achieved in 16 (76.2%) and 55 (88.7%) (p = NS) in group I?and II respectively. Composite endpoints: early safety occurred in 5 (23.8%) and 11 (17.7%) patients (p =NS) in group I?and II respectively; clinical efficacy occurred in 10 (47.6%) and 28 (45.2%) patients (p = NS) in group I?and II respectively. 30-day mortality was 4.8% vs 9.7%, 1-year mortality was 28.6% vs 17.7% (p = NS) in group I?and II respectively. Conclusions TAVI in patients with severe aortic stenosis and BAV is as effective as in patients with TAV using self-expanding prostheses if the valve selection is based on annular sizing.
机译:引言用于经膜管主动脉瓣植入(TAVI)的适应症不断扩大,包括较年轻的患者。 Bicuspid主动脉阀(BAV)经常发生在该组中。为了实现年轻患者的最佳治疗结果,有必要开发一种选择植入阀尺寸的有效方法。目的:将Tavi的结果与a?BAV和A TRICUSPID主动脉瓣膜(TAV)的患者进行了使用?自我扩张的假体,基于环形尺寸的阀门选择。材料和方法BAV和TAV的诊断和测量(环形尺寸)基于多切片计算机断层扫描扫描。八十三名患者接受了一个?自我扩张的核心Valve或Evolut R假体。在群体中?(BAV)(BAV)有21例(25.3%)患者和II组(TAV)62名(74.7%)患者。结果基团在基线临床特征方面没有差异。装置成功在第I组中的16(76.2%)和55(88.7%)(P = NS)中取得了成功?分别为II。复合终点:早期安全发生在第I组中的5(23.8%)和11名(17.7%)患者(P = NS)中发生?和II分别;临床疗效发生在I组中10(47.6%)和28例(45.2%)患者(P = NS)分别发生在1次(分别为II患者。 30天死亡率为4.8%vs 9.7%,1年死亡率为28.6%,分别为17.7%(P = NS)分别为28.6%?结论Tavi在严重主动脉狭窄和BAM患者中,如果阀门选择基于环形尺寸,则使用自扩张假体使用自扩张假体的TAV患者有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号